Study Summary:
Phase III double blind, placebo controlled trial the evaluate the efficacy and safety of investigational medication over 24 weeks in patients with moderate to persistent asthma.
Qualified Participants Must:
• Be 18 to 75 years of age
•
Have been diagnosed with asthma before the age of 40
•
Be on a routine dose of inhaled corticosteroids and still experiencing the symptoms of asthma
Qualified Participants May Receive:
Subjects will receive all study related medication and care at no cost. Eligible participants will be compensated for time and travel, including overnight visits and PK/PG visits.